-+ 0.00%
-+ 0.00%
-+ 0.00%

Evercore ISI Group Maintains Outperform on ProQR Therapeutics, Raises Price Target to $6

Benzinga·06/29/2026 15:00:44
Listen to the news
Evercore ISI Group analyst Gavin Clark-Gartner maintains ProQR Therapeutics (NASDAQ:PRQR) with a Outperform and raises the price target from $5 to $6.